Operator
Good afternoon, women and gents, and welcome to the Santhera Prescribed drugs Half Yr Outcomes Investor Presentation. [Operator Instructions] Earlier than we start, we wish to submit the next ballot. And when you may give that your form consideration, I am certain the corporate can be most grateful. And I’d now like handy you over to the crew from Santhera Prescribed drugs, Catherine and Shabir. Good afternoon.
Catherine Isted
Chief Monetary Officer
Good afternoon, everybody, and welcome once more to the interim outcomes for the 6 months ending the thirtieth of June 2025. Giving the presentation right this moment is myself, Catherine Isted, the CFO; in addition to our Chief Medical Officer, Dr. Shabir Hasham. Sadly, our CEO, Dario Eklund, can’t be with us right this moment as he is truly had a current operation on his shoulder, however he will probably be again with us shortly. As was mentioned within the introduction, there will probably be a chance to ask questions on the finish of the presentation. So please add these into the field as we go alongside.
To begin with, as all the time, now we have the disclaimer. Please be happy to learn this at your leisure. Whereas I admire it is a outcomes name, we thought it is worthwhile spending a little bit of time going by who Santhera is and what we do and in addition a reminder in regards to the DMD market. So I’ll begin off with this small snapshot of the corporate.
So we’re a Swiss listed firm, listed on SIX with our world headquarters in Basel, with about 110 staff, in complete about 150, together with contractors. We’ve a product referred to as AGAMREE. This can be a differentiated product within the Duchenne muscular
